Viking Therapeutics (VKTX) Offers Potential With VK2735 Market Opportunity

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 best mid-cap stocks that could double your money.

On May 28, Lake Street assigned a Buy rating to Viking Therapeutics Inc. (NASDAQ:VKTX) while setting a price target at $89. This leads to an upside potential of more than 211% at the prevailing level.

RAJ CREATIONZS / shutterstock.com

According to the firm, this stance is driven by the market opportunity for VK2735, the company’s lead clinical asset for obesity. VK2735 is projected to generate approximately $3 billion in risk-adjusted worldwide sales by the year 2040. Additionally, the firm noted the potential for further financial upside stemming from the company’s earlier-stage pipeline assets.

On May 27, Truist published a report on Viking Therapeutics Inc. (NASDAQ:VKTX) with a Buy rating and a price target of $83, indicating a 191% upside. The firm highlighted the company as a distinct competitor within a crowded and highly aggressive obesity treatment market.

The company effectively addresses two major hurdles found in existing and emerging treatments, which include long-term patient compliance and rapid time to efficacy, pointing to the achievement of 14.7% weight loss within 13 weeks without hitting a plateau.

Furthermore, Truist emphasized that by offering both the oral and subcutaneous delivery options, the company enables a continuous care model with adaptable dosing and flexible titration. This versatility allows for greater clinical personalization while helping to reduce gastrointestinal side effects.

Viking Therapeutics Inc. (NASDAQ:VKTX) specializes in metabolic and endocrine disorder therapies. As a clinical-stage biopharmaceutical company, they direct their research efforts towards small-molecule drugs to cure obesity, fatty liver, and diabetes.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.